Thus vaccinations with p190-derived peptides could induce in Ph+ ALL patients peptide-specific T cell response that could control or even eradicate minimal residual disease thus reducing the probability of relapse in these patients. The gene discussed is CNTNAP1; the disease is acute lymphoblastic leukemia.